Valeant, Ackman sign deal to acquire Botox-maker Allergan for $45bn - 1 views
-
Alex Parker on 23 Apr 14PBR Staff Writer Published 23 April 2014 Canada-based Valeant Pharmaceuticals (Valeant) and activist investor Bill Ackman have revealed details of their offer to acquire Botox-maker Allergan, in a cash-and-stock deal that could be worth more than $45bn. Under the deal, Allergan investors would receive $48.30 in cash and 0.83 of a Valeant stock for each share they own.